Experimental Ebola vaccine regimen induced durable immune response, study finds

(NIH/National Institute of Allergy and Infectious Diseases) A two-vaccine regimen to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published March 14 in JAMA. The investigational vaccines included Ad26.ZEBOV, developed by Janssen Vaccines& Prevention B.V., of the Janssen Pharmaceutical Companies of Johnson& Johnson, and MVA-BN-Filo, developed by Bavarian Nordic. The NIAID supported the development and testing of the experimental vaccines.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news